



**Dr.med. Jan Fehr**

## Contact

Dr.med. Jan Fehr  
Switzerland

## Publications (39)

Blankenberger J, Kriemler S, Michel G, Rodondi N, Rodondi P, Speierer A, Tancredi S, Puhan M, Kahlert C, Kohler P, Harju E, Fehr J, Kaufmann M, Albanese E, Amati R, Anker D, Camerini A, Chocano-Bedoya P, Cullati S, Cusini A, Corona Immunitas Research Group. Is living in a household with children associated with SARS-CoV-2 seropositivity in adults? Results from the Swiss national seroprevalence study Corona Immunitas. *BMC Med* 2022; 20:233.

Gazzotti A, De Crom-Beer S, Haller S, Hasler T, Anagnostopoulos A, Hatz C, Fehr J. Ready-To-Go Questionnaire – Development and validation of a novel medical pre-travel risk stratification tool. *Travel Medicine and Infectious Disease* 2022; 47

Kahlert C, Albrich W, Babouee Flury B, Besold U, Fehr J, Kuster S, McGeer A, Risch L, Schlegel M, Friedl A, Vernazza P, Wiggli B, Vuichard-Gysin D, Stocker R, Persi R, Güsewell S, Egger T, Leal-Neto O, Sumer J, Flury D, Brucher A, Lemmenmeier E, Möller J, Rieder P, Kohler P. Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers – A multicentre cross-sectional study. *Clin Microbiol Infect* 2021; 27:1336–1344.

Künzler-Heule P, Fehr J, Braun D, Schmid P, Kouyos R, Lehner A, Nöstlinger C, Battegay M, Engberg S, Kocher A, Bogdanovic J, Rasi M, Schmidt A, Fierz K, Nicca D. Response to a sexual risk reduction intervention provided in combination with hepatitis C treatment by HIV/HCV co-infected men who have sex with men: a reflexive thematic analysis. *BMC Infect Dis* 2021; 21:319.

Carlisle L, Günthard H, Bernasconi E, Vernazza P, Stoeckle M, Cavassini M, Nguyen A, Yerly S, Rauch A, Salazar-Vizcaya L, Fehr J, Braun D, Huber M, Böni J, Shah C, Mbunkah H, Metzner K, Turk T, Kouyos R. HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection. *Viruses* 2020; 12

West E, Michel G, Gonseth S, Guessous I, Imboden M, Kahlert C, Kaufmann L, Kohler P, Möslig N, Paris D, Probst-Hensch N, Rodondi N, Stringhini S, Vermes T, Vollrath F, Puhan M, Frei A, Frank I, Anker D, Amati R, Richard A, Wisniak A, Butty A, Albanese E, Bochud M, Chiolero A, Crivelli L, Cullati S, d'Acremont V, Epure A, Fehr J, Flahault A, Fornerod L, Corona Immunitas Research Group. Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland. *Int J Public Health* 2020

Schreiner P, Rogler G, Juillerat P, Vavricka S, Vulliemoz M, Restellini S, Schoepfer A, Michetti P, Brand S, Maillard M, Fehr J, Mueller N, Biedermann L. Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. *J Crohns Colitis* 2020

Salazar-Vizcaya L, Kouyos R, Günthard H, Schmid P, Bernasconi E, Darling K, Fehr J, Braun D, Wandeler G, Nicca D, Carrillo-Montoya G, Schmidt A, Kusejko K, Rauch A. Clusters of Sexual Behavior in Human Immunodeficiency Virus-positive Men Who Have Sex With Men Reveal Highly Dissimilar Time Trends. *Clin Infect Dis* 2020; 70:416–424.

Künzler-Heule P, Nicca D, Fehr J, Braun D, Rougement M, Flepp M, Schmid P, Delaloye J, Béguelin C, Stöckle M, Hampel B, Nöstlinger C, Kocher A, Nguyen H, Fierz K, Schmidt A, Battegay M, Engberg S, Swiss HIV Cohort Study (SHCS). Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis. *BMC Infect Dis* 2019; 19:821.

Salazar-Vizcaya L, Rauch A, Béguelin C, Rougemont M, Hoffmann M, Bernasconi E, Stoeckle M, Cavassini M, Braun D, Fehr J, Wandeler G, Swiss HIV Cohort Study. Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study. *Open Forum Infect Dis* 2018; 5:ofy154.

Damonti L, Frei R, Orasch C, Conen A, Khanna N, Bregenzer T, Bille J, Lamoth F, Marchetti O, Bochud P, Fluckiger U, Bruderer T, Erard V, Garbino J, Schrenzel J, Zimmerli S, Mühlenthaler K, Imhof A, Zbinden R, Fehr J, Boggian K, Fungal Infection Network of Switzerland (FUNGINOS). Correction to: Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia. *Intensive Care Med* 2018

Orasch C, Fluckiger U, Conen A, Khanna N, Frei R, Bregenzer T, Lamoth F, Erard V, Bochud P, Calandra T, Bille J, Marchetti O, Bruderer T, Boggian K, Zbinden R, Mertz D, Garbino J, Van Delden C, Emonet S, Schrenzel J, Zimmerli S, Damonti L, Mühlenthaler K, Imhof A, Ruef C, Fehr J, Fungal Infection Network of Switzerland (FUNGINOS). Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study. *J Infect* 2018

Bachofner J, Mertens J, Terzioli Beretta-Piccoli B, Mullhaupt B, Magenta L, Semela D, Fehr J, Moncsek A, Seifert B, Braun D, Baserga A, Künzler-Heule P, Kröger A, Bergamin I, Valli P, The Swiss Hepatitis C Cohort Study. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland. *Swiss Med Wkly* 2018; 148:w14560.

Bruggmann P, Stoeckle M, Semela D, Schmid P, Razavi H, Rauch A, Mullhaupt B, Lavanchy D, Kouyos R, Fehr J, Deltenre P, Blach S, Negro F. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. *Swiss Med Wkly* 2017; 147:w14543.

Béguin C, Rauch A, Wandeler G, Schmid P, Rougemont M, Cavassini M, Stoeckle M, Bucher H, Kovari H, Fehr J, Bernasconi E, Suter A, Swiss HIV Cohort Study. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study. *Liver Int* 2017

Sculier D, Calmy A, Bernasconi E, Schmid P, Hirzel C, Fehr J, Cavassini M, Battegay M, Gayet-Ageron A, Swiss HIV Cohort Study. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. *BMC Infect Dis* 2017; 17:476.

Damonti L, Frei R, Orasch C, Conen A, Khanna N, Bregenzer T, Bille J, Lamoth F, Marchetti O, Bochud P, Fluckiger U, Bruderer T, Erard V, Garbino J, Schrenzel J, Zimmerli S, Mühlenthaler K, Imhof A, Zbinden R, Fehr J, Boggian K, Fungal Infection Network of Switzerland (FUNGINOS). Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia. *Intensive Care Med* 2017; 43:935–939.

Bachofner J, Mullhaupt B, Terzioli Beretta-Piccoli B, Magenta L, Semela D, Fehr J, Moncsek A, Seifert B, Braun D, Baserga A, Künzler-Heule P, Bergamin I, Kröger A, Valli P, Mertens J. DAA treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers FIB-4 and APRI. *Liver Int* 2016

Stucki D, Jaton K, Rieder H, Pfyffer G, Siegrist H, Hoffmann M, Fehr J, Dolina M, Frei R, Schrenzel J, Böttger E, Gagneux S, Mazza Stalder J, Calmy A, Ballif M, Egger M, Furrer H, Altpeter E, Battegay M, Droz S, Bruderer T, Coscolla M, Borrell S, Zürcher K, Janssens J, Fenner L. Standard Genotyping Overestimates Transmission of *Mycobacterium tuberculosis* among Immigrants in a Low-Incidence Country. *J Clin Microbiol* 2016; 54:1862–70.

Wandeler G, Furrer H, Bernasconi E, Schmid P, Battegay M, Orasch C, Calmy A, Conen A, Fehr J, Kraus D. The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events. *J Acquir Immune Defic Syndr* 2016; 71:302–9.

Elzi L, Furrer H, Bernasconi E, Schmid P, Calmy A, Cavassini M, Fehr J, Patzen A, Conen A, Battegay M. Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study. *Open Forum Infect Dis* 2016; 3:ofw022.

Ciaffi L, Calmy A, Montecucco F, Hirschl B, Schmid P, Stoeckle M, Fehr J, Wandeler G, Hill A, Spycher Elbes R, Delhumeau C, Genné D, Cavassini M, Swiss HIV Cohort Study. Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study. *Eur J Clin Invest* 2015

Itin P, Schmid P, Bernasconi E, Harry D, Boffi El Amari E, Herold M, Klimkait T, Kahlert C, Furrer H, Lautenschlager S, Calmy A, Cavassini M, Oertle D, Low N, Bosshard P, Toutous-Treliu L, Schmidt A, Vernazza P, Tarr P, Stoeckle M, Wymann M, Ciardo D, Class J, Scheidegger C, Fehr J. Syphilis: Diagnostik und Behandlung – Aktualisierte Empfehlungen der Eidgenössischen Kommission für Sexuelle Gesundheit. Schweizerisches Medizin-Forum 2015; 15:459–465.

Yerly S, Metzner K, Martinez de Tejada B, Martinetti G, Ledergerber B, Kovari H, Kouyos R, Klimkait T, Keiser O, Kaiser L, Kahlert C, Hösli I, Hoffmann M, Hirsch H, Hasse B, Müller N, Nadal D, Weber R, Vernazza P, Trkola A, Telenti A, Tarr P, Speck R, Schüpbach J, Schöni-Affolter F, Rudin C, Rickenbach M, Regenass S, Rauch A, Pantaleo G, Nicca D, Haerry D, Günthard H, Gorgievski M, Rauch A, Furrer H, Salazar-Vizcaya L, Keiser O, Bernasconi E, Schmid P, Stöckle M, Cavassini M, Ambrosioni J, Fehr J, Metzner K, Rohrbach J, Jaquier M, Schlauri M, Swiss HIV Cohort Study, Aubert V, Fux C, Furrer H, Fellay J, Fehr J, Elzi L, Egger M, Dollenmaier G, Cavassini M, Calmy A, Burton-Jeangros C, Bucher H, Böni J, Bernasconi E, Battegay M, Wandeler G. Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. Open Forum Infect Dis 2015; 2:ofv026.

Carballo D, Calmy A, Ledergerber B, Keller P, Erne P, Fehr J, Cusini A, Schmid P, Fasel D, Bernasconi E, Clerc O, Hirschel B, Radovanovic D, Bähler C, Carballo S, Delhumeau C, Swiss HIV Cohort Study and AMIS registry. Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients: a nested cohort study. AIDS Res Ther 2015; 12:4.

Rasi M, Künzler-Heule P, Schmid P, Semela D, Bruggmann P, Fehr J, Sixer S, Nicca D. "Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis. BMC Infect Dis 2014; 14:507.

Wang Q, Battegay M, Bucher H, Fehr J, Furrer H, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Young J, Swiss HIV Cohort Study. Virologic and immunologic responses in treatment-naïve patients to ritonavir-boosted atazanavir or efavirenz with a common backbone. HIV Clin Trials 2014; 15:92–103.

Hasse B, Ledergerber B, Weber R, Di Benedetto C, Fellay J, Calmy A, Battegay M, Hoffmann M, Furrer H, Fehr J, Walker A, Swiss HIV Cohort Study. Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. Antimicrob Agents Chemother 2014; 58:2363–8.

Conen A, Battegay M, Bucher H, Weber R, Vernazza P, Bernasconi E, Calmy A, Orasch C, Thurnheer M, Fux C, Glass T, Wang Q, Fehr J. Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study. J Acquir Immune Defic Syndr 2013; 64:472–8.

Aebi-Popp K, European Collaborative Study in EuroCoord, Thorne C, Hoesli I, Rickenbach M, Scheibner K, Grawe C, Fehr J, Bertisch B, Martinez de Tejada B, Rudin C, Glass T, Mulcahy F, Swiss Mother & Child HIV Cohort Study. Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery. J Acquir Immune Defic Syndr 2013; 64:58–65.

Fenner L, Cavassini M, Calmy A, Dolina M, Frei R, Janssens J, Borrell S, Stucki D, Schrenzel J, Böttger E, Gagneux S, Bernasconi E, Hoffmann M, Egger M, Bodmer T, Furrer H, Ballif M, Battegay M, Helbling P, Fehr J, Gsponer T, Rieder H, Zwahlen M, Swiss HIV Cohort and Molecular Epidemiology of Tuberculosis Study Groups. HIV Infection Disrupts the Sympatric Host-Pathogen Relationship in Human Tuberculosis. PLoS Genet 2013; 9:e1003318.

Boillat-Blanco N, Wandeler G, Fehr J, Daou S, Elzi L, Adamo M, Strahm C, Osih R, Taffé P, Darling K, Cavassini M. Impact of recommendation updates in well-controlled patients on nonrecommended antiretroviral therapies: the Swiss HIV cohort study. J Acquir Immune Defic Syndr 2013; 62:180–9.

Fenner L, Egger M, Helbling P, Böttger E, Bodmer T, Schrenzel J, Bernasconi E, Hoffmann M, Cavassini M, Fehr J, Janssens J, Gagneux S, Swiss HIV Cohort and Molecular Epidemiology of Tuberculosis Study Groups. Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes. PLoS one 2012; 7:e34186.

Elzi L, Bassetti S, Bernasconi E, Hoffmann M, Hirschel B, Cavassini M, Fehr J, Furrer H, Steffen I, Battegay M. Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection. *BMC Infect Dis* 2011; 11:319.

Fehr J, Hirschel B, Vernazza P, Martinetti G, Bernasconi E, Günthard H, Battegay M, Bucher H, Klimkait T, Fux C, Cavassini M, Glass T, Louvel S, Hamy F, Hirsch H, von Wyl V, Böni J, Yerly S, Bürgisser P, Hiv Cohort Study A. Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals – the Swiss HIV Cohort Study. *J Transl Med* 2011; 9:14.

Dang T, Tarr P, Odorico M, Cavassini M, Boffi El Amari E, Schmid P, Fehr J, Evison J, Kovari H, Flepp M, Jaton-Ogay K, Greub G. High prevalence of anorectal chlamydial infection in HIV-infected men who have sex with men in Switzerland. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2009; 49:1532–5.

Conen A, Battegay M, Bucher H, Bernasconi E, Cavassini M, Hirschel B, Vernazza P, Weber R, Furrer H, Glass T, Fehr J, Swiss HIV Cohort Study. Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. *Antiviral therapy* 2009; 14:349–57.

Nicca D, Fehr J, Battegay M, Spirig R. [Ready for antiretroviral therapy? Therapy decision making experiences of persons living with HIV]. *Pflege* 2005; 18:289–98.

Fehr J, Spirig R, Jäger H, Vernazza P, Bregenzer T, Kiss A, Wagels T, Wolf E, Sendi P, Nicca D, Battegay M. Starting or changing therapy – a prospective study exploring antiretroviral decision-making. *Infection* 2005; 33:249–256.

## Projects (1)

### **Positive Deviance in der Hepatitis C Behandlung**

*Clinical Studies - Nov 15, 2013 - Feb 28, 2015*

*Automatically Closed*

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)